ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Zoetis Debuts With $2.2 Billion IPO

by Rick Mullin
February 11, 2013 | APPEARED IN VOLUME 91, ISSUE 6

Zoetis, the former Pfizer animal health business, has raised $2.2 billion in its initial public offering, the biggest IPO since Facebook’s $16 billion launch last May. Pfizer announced the creation of Zoetis last June. The unit had sales of more than $4 billion in 2011. “With the Zoetis initial public offering, we are creating the largest stand-alone company fully devoted to animal health medicines and vaccines,” says Pfizer CEO Ian Read. “For Pfizer, we are better positioned to focus on our core business as an innovative biopharmaceutical company.” Pfizer earlier sold drug capsule and nutrition businesses as part of its program to shed noncore operations.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment